Safety Study of Calcineurin Inhibitor Free GvHD Prophylaxis in Allogeneic Stem Cell Transplantation
Status:
Unknown status
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
In stem cell transplantation as treatment for malignant diseases, calcineurin inhibitors like
cyclosporine A are commonly used to prevent tissue destruction (GvHD) by activated donor
immune cells. The hypothesis for this study is, that replacing calcineurin inhibitors by
everolimus and mycophenolate as GvHD prophylaxis not only reduces toxicity of the treatment
but also improves tolerance induction of the donor T cells toward the host, eventually
increasing the safety of stem cell transplantation.